4A 10
Alternative Names: 4A-10; 4A10 antibody therapy - Allterum TherapeuticsLatest Information Update: 04 Jul 2025
At a glance
- Originator National Cancer Institute (USA)
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Precursor T-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 25 Apr 2025 Pharmacodynamic data from a preclinical trial in Acute lymphoblastic leukemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 08 Oct 2024 4A 10 is still in preclinical trials for Precursor T-cell lymphoblastic leukaemia-lymphoma in the US (Parenteral)
- 08 Oct 2024 4A 10 receives Orphan Drug status for Precursor T-cell lymphoblastic leukaemia-lymphoma in USA